PD-L1, CD47 and now CD24? Star Stanford I/O scientist Irv Weissman points to a ‘major’ new cancer target
Famed Stanford drug researcher Irv Weissman, who helped set off a scramble to develop new drugs that can silence the “don’t eat me” signal sent by CD47, says he and a team of investigators in his lab have found a complementary target on the menu that promises to work where the pioneering drugs fall far short of the mark.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,400+ biopharma pros reading Endpoints daily — and it's free.